ClinicalTrials.gg
CompletedNCT02589639Updated Mar 27, 2019Results posted

Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus

A Phase 4 interventional study of Empagliflozin and Placebo in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 48 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2019-03-27.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
269
Allocation
Randomized
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.

Enrollment
29th of 130
269 · median 79
Started
2015
with 4 others
Phase 4
50 of 130
11 open now
Registered
35th of 130
by date
Lead sponsor
37 of 130
Boehringer Ingelheim

Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 29th largest by enrollment, is one of 5 that started in 2015, is one of 50 in phase 4, and was the 35th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 20 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a multi-center, randomised, double-blind, placebo-controlled, parallel-group, efficacy and safety study of empagliflozin as add-on to insulin in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic control

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of type 2 diabetes mellitus
  • Patients on diet and exercise regimen who are pre-treated with any insulin therapy alone or in combination with 1 oral antidiabetic drug for at least 12 weeks prior to screening
  • Fasting C-peptide must be > 0.5 ng/mL
  • at screening in Patients who are treated with insulin alone must be >=7.5% and \<=10.0%
  • HbA1c in Patients who are treated with insulin with 1 oral antidiabetic drug (OAD) must be >=7.0% and \<=9.5% at screening, and >=7.5% and \<=10.0% at placebo run-in period
  • Age at must be >=20 and \<75 years
  • at screening must be >22 and \<=40 kg/m2
  • Further inclusion criteria apply

Exclusion criteria

Exclusion criteria:

  • Patients who experience uncontrolled hyperglycaemia before randomization
  • Patients who are treated with sulfonylurea whose dose is more than a half of daily maximum approval dose, glucagon-like peptide-1 (GLP-1) analogue, thiazolidinedione and sodium-glucose co-transporter 2 (SGLT-2) inhibitor
  • Patients with recent cardiovascular and/or stroke events
  • Patients with hepatic and/or renal dysfunction
  • Patients who received anti-obesity drugs or other treatment leading to unstable body weight
  • Patients who have known allergy or to insulin and/or empagliflozin
  • Pre-menopausal women who are nursing or pregnant
  • Further exclusion criteria apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
269 participants (actual)

Study arms

  • Experimental
    empagliflozin 10 mg

    Drug: Empagliflozin · Drug: Placebo

  • Experimental
    empagliflozin 25 mg

    Drug: Empagliflozin · Drug: Placebo

  • Placebo comparator
    placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 16 Weeks of Treatment.

    The primary endpoint was the change from baseline in HbA1c after 16 weeks of treatment. The term "baseline" refers to the last observation prior to the administration of any randomised study drug. Means presented are the adjusted means.

    Time frame: Baseline and 16 weeks

Secondary outcomes

  1. Percentage of Patients With Investigator Defined Drug-Related Adverse Events (AEs)

    Percentage of patients with investigator defined drug-related Adverse Events (AEs) are presented

    Time frame: From 1st intake of study drug to last intake of study drug + 7 days; up to 53 weeks

07

Results

Posted Mar 27, 2019

Participant flow

After screening, patients who were pre-treated with insulin and 1 oral antidiabetic drug (OAD) underwent a 10-week wash-out period. Then patients proceeded to a 2-week open-label placebo run-in period. Patients who were pre-treated with insulin alone skipped the wash-out period and proceeded to an open-label placebo run-in period.

Participant flow — Overall Study
MilestonePlaceboEmpagliflozin 10 mgEmpagliflozin 25 mg
Started908990
Treated908690
Completed807986
Not completed10104
Withdrew: Lost to follow-up100
Withdrew: Protocol violation100
Withdrew: Patient withdrawal, not due to ae300
Withdrew: Adverse event453
Withdrew: Other reason than specified above121
Withdrew: Not treated030

Outcome measures

PrimaryChange From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 16 Weeks of Treatment.

The primary endpoint was the change from baseline in HbA1c after 16 weeks of treatment. The term "baseline" refers to the last observation prior to the administration of any randomised study drug. Means presented are the adjusted means.

Time frame:
Baseline and 16 weeks
Reported as:
Mean · percentage of HbA1c
Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 16 Weeks of Treatment.
percentage of HbA1cPlaceboEmpagliflozin 10 mgEmpagliflozin 25 mg
Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 16 Weeks of Treatment.0.00 ± 0.07-0.92 ± 0.07-1.00 ± 0.07
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · ANCOVA · p = <0.0001 · Mean difference (final values): -0.92 · 95% CI -1.11 to -0.73Analysis of Covariance (ANCOVA) comparing the change from baseline in HbA1c after 16 weeks of treatment
  • Placebo vs Empagliflozin 25 mg · ANCOVA · p = <0.0001 · Mean difference (final values): -1.00 · 95% CI -1.18 to -0.82Adjusted Mean Difference calculated as (Empagliflozin 10 mg - Placebo)
SecondaryPercentage of Patients With Investigator Defined Drug-Related Adverse Events (AEs)

Percentage of patients with investigator defined drug-related Adverse Events (AEs) are presented

Time frame:
From 1st intake of study drug to last intake of study drug + 7 days; up to 53 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients With Investigator Defined Drug-Related Adverse Events (AEs)
Percentage of participantsPlaceboEmpagliflozin 10 mgEmpagliflozin 25 mg
Percentage of Patients With Investigator Defined Drug-Related Adverse Events (AEs)25.643.043.3

Adverse events

Collected over From 1st intake of study drug to last intake of study drug + 7 days; up to 53 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/90 (0%)6/90 (6.7%)49/90 (54.4%)
Empagliflozin 10 mg1/86 (1.2%)9/86 (10.5%)45/86 (52.3%)
Empagliflozin 25 mg0/90 (0%)8/90 (8.9%)48/90 (53.3%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventPlaceboEmpagliflozin 10 mgEmpagliflozin 25 mg
GlaucomaEye disorders0/900/862/90
Arthritis bacterialInfections and infestations0/901/860/90
Chronic sinusitisInfections and infestations0/901/860/90
Pyelonephritis acuteInfections and infestations0/901/860/90
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/901/860/90
Disseminated intravascular coagulationBlood and lymphatic system disorders0/901/860/90
DeliriumPsychiatric disorders0/901/860/90
Vocal cord paralysisNervous system disorders0/901/860/90
Coronary artery stenosisCardiac disorders0/901/860/90
Myocardial infarctionCardiac disorders0/901/860/90
Most frequent other events
Most frequent other events
EventPlaceboEmpagliflozin 10 mgEmpagliflozin 25 mg
NasopharyngitisInfections and infestations28/9030/8624/90
HypoglycaemiaMetabolism and nutrition disorders19/9024/8625/90
PollakiuriaRenal and urinary disorders2/909/869/90
Asymptomatic bacteriuriaInfections and infestations8/903/865/90
Back painMusculoskeletal and connective tissue disorders3/905/866/90
EczemaSkin and subcutaneous tissue disorders5/905/862/90
Blood ketone body increasedInvestigations1/905/862/90

Baseline characteristics

The full analysis set (FAS) consisted of all patients in the treated set (TS) who had a baseline measurement of the primary endpoint. (The treated set (TS) consisted of all randomised patients who were treated with at least 1 dose of the study drug during the 52-week double blind treatment period. The TS was the basis for safety analyses)

Age, Continuous
Age, Continuous(years)Empagliflozin 10 mgEmpagliflozin 25 mgPlaceboTotal
Mean59.1 ± 10.758.3 ± 10.058.6 ± 9.558.7 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)Empagliflozin 10 mgEmpagliflozin 25 mgPlaceboTotal
Female21232973
Male696361193
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Empagliflozin 10 mgEmpagliflozin 25 mgPlaceboTotal
Count of participants———0
Baseline glycosylated haemoglobin A1c (HbA1c) [%]
Baseline glycosylated haemoglobin A1c (HbA1c) [%](% of HbA1c)Empagliflozin 10 mgEmpagliflozin 25 mgPlaceboTotal
Mean8.70 ± 0.688.83 ± 0.668.74 ± 0.728.75 ± 0.69
08

Study locations

48 sites
  • Nakayama Clinic
    Aichi, 456-0058, Japan
  • Kashiwa City Hospital
    Chiba, Kashiwa, 277-0825, Japan
  • Saiseikai Fukuoka General Hospital
    Fukuoka, Fukuoka, 810-0001, Japan
  • Seiwakai Medical Corporation Nagata Hospital
    Fukuoka, Yanagawa, 832-0059, Japan
  • Kunisaki Makoto Clinic
    Fukuoka, 819-0168, Japan
  • Saiseikai Maebashi Hospital
    Gunma, Maebashi, 371-0821, Japan
  • Nippon Kokan Fukuyama Hospital
    Hiroshima, Fukuyama, 721-0927, Japan
  • Jiyugaoka Yokoyama Naika Clinic
    Hokkaido, Obihiro, 080-0016, Japan
  • Jiyugaoka Yamada Clinic
    Hokkaido, Obihiro, 080-0848, Japan
  • Souen Diabetes Clinic
    Hokkaido, Sapporo, 060-0011, Japan
  • Kotani Diabetes Clinic
    Hyogo, Kobe, 657-0028, Japan
  • Nishinomiya Municipal Central Hospital
    Hyogo, Nishinomiya, 663-8014, Japan
  • Noritake Clinic
    Ibaraki, Ushiku, 300-1207, Japan
  • Yokoi Medical Clinic, Kagawa, I.M.
    Kagawa, 761-8075, Japan
  • Izuro Imamura Hospital
    Kagoshima, Kagoshima, 892-0824, Japan
  • Wakamatsu Memorial Hospital
    Kagoshima, Satsumasendai, 895-0052, Japan
  • Fukumoto clinic
    Kagoshima, 891-0401, Japan
  • STOP DM SUZUKI DIABETES CLINIC, Kanagawa, I.M.
    Kanagawa, Atsugi, 243-0035, Japan
  • Takai Naika Clinic
    Kanagawa, Kamakura, 247-0056, Japan
  • Kokan Clinic
    Kanagawa, Kawasaki, 210-0852, Japan
  • Yoshimasa Diabetes & Endocrine Clinic
    Kyoto, Kyoto, 604-8151, Japan
  • Medical Corporation KEISEIKAI Kajiyama clinic
    Kyoto, kyoto, 615-0035, Japan
  • Saka General Clinic
    Miyagi, Tagajo, 985-0835, Japan
  • North Alps Medical Center Azumi Hospital
    Nagano, Kitaazumi-gun, 399-8695, Japan
  • Asama Nanroku Komoro Medical center
    Nagano, Komoro, 384-8588, Japan
  • Abe Clinic
    Oita, Oita, 870-0039, Japan
  • Tsuyama Chuo Hospital
    Okayama, Tsuyama, 708-0841, Japan
  • Medical Corporation Kyojinkai Clinic Komatsu
    Osaka, Neyagawa, 572-8567, Japan
  • Minamiosaka Hospital
    Osaka, Osaka, 559-0012, Japan
  • OCROM Clinic
    Osaka, Suita, 565-0853, Japan
  • AMC Nishi-umeda Clinic
    Osaka, 530-0001, Japan
  • Shiraiwa Medical Clinic
    Osaka, 582-0005, Japan
  • Ageo Central General Hospital
    Saitama, Ageo, 362-8588, Japan
  • Medical Corporation Kaishinkai Masunaga Clinic
    Saitama, Fujimi, 354-0031, Japan
  • Medical Corporation Fusa Shimizu Clinic Fusa
    Saitama, Saitama, 336-0963, Japan
  • Seiwa Clinic
    Tokyo, Adachi-ku, 123-0845, Japan
  • Juntendo University Hospital
    Tokyo, Bunkyo-ku, 113-8431, Japan
  • Chiyoda Houjin Clinic
    Tokyo, Chiyoda-ku, 101-0024, Japan
  • HDC Atlas Clinic
    Tokyo, Chiyoda-ku, 102-0082, Japan
  • Fukuwa Clinic
    Tokyo, Chuo-ku, 103-0027, Japan
  • Tokyo-Eki Center-building Clinic
    Tokyo, Chuo-ku, 103-0027, Japan
  • Tokyo Center Clinic
    Tokyo, Chuo-ku, 103-0028, Japan
  • Shin Clinic
    Tokyo, Ota-ku, 144-0051, Japan
  • Shinjuku Research Park Clinic
    Tokyo, Shinjuku-ku, 169-0073, Japan
  • Sumida Chuou Hospital
    Tokyo, Sumida-ku, 131-0046, Japan
  • Sagae City Hospital
    Yamagata, Sagae, 991-8508, Japan
  • Clinic Sugiyama
    Yamagata, Yamagata, 990-0885, Japan
  • Yamanashi Prefectural Central Hospital
    Yamanashi, Kofu, 400-8506, Japan
09

References and documents

Publications

  • Tuttle KR, Levin A, Nangaku M, Kadowaki T, Agarwal R, Hauske SJ, Elsasser A, Ritter I, Steubl D, Wanner C, Wheeler DC. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Diabetes Care. 2022 Jun 2;45(6):1445-1452. doi: 10.2337/dc21-2034. PubMed 35472672 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Apr 2017, 17 months.

Results were first posted in Mar 2019, 1 year 11 months after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 17 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2015
First posted
Oct 28, 2015
StartActual
Oct 28, 2015
Primary completionActual
Apr 18, 2017
CompletionActual
Jan 5, 2018
Results first posted
Mar 27, 2019
Last update
Mar 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02589639
Responsible party
Sponsor
First posted
Oct 28, 2015
Start date
Oct 28, 2015
Primary completion
Apr 18, 2017
Completion
Jan 5, 2018
Results posted
Mar 27, 2019
Last update
Mar 27, 2019

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion